{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T16:32:23Z","timestamp":1770741143103,"version":"3.49.0"},"reference-count":11,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Clin Nucl Med"],"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Carcinoid heart disease (Hedinger syndrome) is a long-term consequence in hormone-active neuroendocrine tumors with hepatic metastases and carcinoid syndrome. Because of serotonin, excess multiple cardiac and pulmonary symptoms evolve, which are further complicated by a patent foramen ovale due to right-left shunting. We present a 53-year-old man with an ileum-neuroendocrine tumor including gross liver metastases and long-term stable disease who subsequently developed Hedinger syndrome. Initially experiencing progressive dyspnea, he eventually experienced severe hypoxemia due to patent foramen ovale. <jats:sup>99m<\/jats:sup>Tc-MAA lung perfusion scintigraphy quantitatively identified the right-left shunting, whereas <jats:sup>68<\/jats:sup>Ga-FAPI-46 PET\/CT characterized the typical fibrous heart valve thickening due to serotonin-induced fibroblast proliferative properties.<\/jats:p>","DOI":"10.1097\/rlu.0000000000005004","type":"journal-article","created":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T06:01:22Z","timestamp":1704434482000},"page":"157-159","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["NET-Induced Carcinoid Heart Disease Affecting Both Tricuspid and Aortic Valves Due to Patent Foramen Ovale and Right\/Left Shunt"],"prefix":"10.1097","volume":"49","author":[{"given":"Christina","family":"Laschinsky","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Welsner","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine, University Hospital Essen\u2013Ruhrlandklinik, University of Duisburg-Essen"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amir A.","family":"Mahabadi","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Vascular Medicine, West German Heart and Vascular Center Essen, University Hospital Essen"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harald","family":"Lahner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hubertus","family":"Hautzel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"bib1-20250621","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1097\/MNM.0b013e32834a123f","article-title":"Cut-off value for normal versus abnormal right-to-left shunt percentages using (99m)Tc-macroaggregated albumin","volume":"32","year":"2011","journal-title":"Nucl Med Commun"},{"key":"bib2-20250621","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S1470-2045(17)30110-9","article-title":"Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study","volume":"18","year":"2017","journal-title":"Lancet Oncol"},{"key":"bib3-20250621","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1136\/hrt.2004.040329","article-title":"Carcinoid heart disease: presentation, diagnosis, and management","volume":"90","year":"2004","journal-title":"Heart"},{"key":"bib4-20250621","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1016\/S1470-2045(21)00572-6","article-title":"177Lu-Dotatate plus long-acting octreotide versus high\u2010dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial","volume":"22","year":"2021","journal-title":"Lancet Oncol"},{"key":"bib5-20250621","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1161\/01.CIR.87.4.1188","article-title":"Carcinoid heart disease. Clinical and echocardiographic spectrum in 74 patients","volume":"87","year":"1993","journal-title":"Circulation"},{"key":"bib6-20250621","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.etp.2008.03.005","article-title":"5-hydroxytryptamine (5HT)-induced valvulopathy: compositional valvular alterations are associated with 5HT2B receptor and 5HT transporter transcript changes in Sprague-Dawley rats","volume":"60","year":"2008","journal-title":"Exp Toxicol Pathol"},{"key":"bib7-20250621","first-page":"e1","article-title":"Assessment of patent foramen ovale in carcinoid heart disease","volume":"151","year":"2006","journal-title":"Am Heart J"},{"key":"bib8-20250621","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.amjcard.2007.11.056","article-title":"Prevalence of patent foramen ovale and usefulness of percutaneous closure device in carcinoid heart disease","volume":"101","year":"2008","journal-title":"Am J Cardiol"},{"key":"bib9-20250621","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.ahj.2014.03.018","article-title":"Carcinoid heart disease: current understanding and future directions","volume":"167","year":"2014","journal-title":"Am Heart J"},{"key":"bib10-20250621","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/j.jacc.2016.12.030","article-title":"Diagnosing and managing carcinoid heart disease in patients with neuroendocrine tumors: an expert statement","volume":"69","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"bib11-20250621","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1159\/000381930","article-title":"Carcinoid heart disease: from pathophysiology to treatment\u2014\u2018something in the way it moves\u2019","volume":"101","year":"2015","journal-title":"Neuroendocrinology"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000005004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T19:03:32Z","timestamp":1750532612000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000005004"}},"subtitle":["A Multi-imaging Challenge to Nuclear Medicine"],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":11,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000005004","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"value":"1536-0229","type":"electronic"},{"value":"0363-9762","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]}}}